Elute, Inc

Elute, Inc., founded in 2018 and based in Cambridge, USA, is an emerging private company pioneering a novel drug-eluting platform for orthopedic applications. Its core technology involves polymer-controlled release of therapeutics from implantable materials, with its lead program, BonVie+™, in a pivotal Phase 2/3 clinical trial (MAGIC) for treating periprosthetic joint infections (PJI). The company is led by a team of technical and clinical experts, including co-founders with deep expertise in biomaterials science, and is positioned to address a large, costly, and growing market for bone graft substitutes and infection prevention in orthopedic surgery.

Patented polymer-based platform for creating resorbable, drug-eluting bone void fillers (BVFs) that provide controlled, sustained, and localized release of therapeutics (e.g., antibiotics) over extended periods (e.g., 8 weeks).

Elute competes in the bone graft substitute and orthopedic infection prevention markets. Direct competitors include companies marketing antibiotic-loaded bone cements (e.g., Zimmer Biomet's Simplex P with Tobramycin) and other antibiotic-eluting technologies. Its key differentiation is the combination of a resorbable bone void filler with sustained, polymer-controlled antibiotic release over 8 weeks, a feature not standard in currently available products.